Which drug stops joint damage best in early psoriatic arthritis?

NCT ID NCT07486843

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a TNF inhibitor (adalimumab biosimilar) is better than methotrexate at preventing bone damage in people with early psoriatic arthritis. About 108 adults with active disease and symptoms for less than 2 years will be randomly assigned to one of the two drugs. Researchers will use a special 3D scan to measure joint damage at the start, 24 weeks, and 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Methotrexate or adalimumab biosimilar (Amgevita)
What this could lead to: If it works, this could show which treatment better prevents permanent joint damage in early psoriatic arthritis.
What could go wrong: This is a small, early-phase trial (108 people) comparing two existing drugs, so results may not apply to everyone. Both drugs have known side effects like infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS (PSA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIATIC ARTHRITIS (PSA)

Contacts and locations

Locations

The Chinese University of Hong Kong, Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.